RT Book, Section
A1 Sievers, Amy
A1 LaCasce, Ann
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127648216
T1 Follicular Lymphoma
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127648216
RD 2024/04/19
AB Follicular  lymphoma  (FL)  represents  20%–30%  of  all  non-Hodgkin  lymphomas  (NHL)  and  is  the  second  most  common  NHL  in  Western  populations  after  diffuse  large  B-cell  lymphoma  (DLBCL)  (1).  FL  comprises  about  80%  of  the  indolent  NHLs.  The  term  follicular  is  derived  from  the  tendency  of  the  neoplastic  cells  to  form  microscopic  nodules.  The  cell  of  origin  is  the  follicular  center  B  cell.  Eighty-five  to  90%  of  all  cases  harbor  the  characteristic  cytogenetic  translocation  t(14;18),  resulting  in  the  placement  of  the  anti-apoptotic  bcl-2  gene  under  the  control  of  the  immunoglobulin  (Ig)  heavy-chain  promoter  on  chromosome  14.  Follicular  lymphoma  is  considered  incurable  without  stem-cell  transplantation,  with  the  exception  of  localized  disease  that  may  be  cured  with  radiotherapy  in  a  subset  of  patients.  Treatment  is  therefore  based  on  disease  control  rather  than  cure,  and  eventual  relapse  after  treatment  is  the  usual  natural  history  of  FL  (2).